Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes.
Pharmacogenomics
; 22(10): 603-618, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-1278319
ABSTRACT
Aim:
Numerous drugs are being widely prescribed for COVID-19 treatment without any direct evidence for the drug safety/efficacy in patients across diverse ethnic populations. Materials &methods:
We analyzed whole genomes of 1029 Indian individuals (IndiGen) to understand the extent of drug-gene (pharmacogenetic), drug-drug and drug-drug-gene interactions associated with COVID-19 therapy in the Indian population.Results:
We identified 30 clinically significant pharmacogenetic variants and 73 predicted deleterious pharmacogenetic variants. COVID-19-associated pharmacogenes were substantially overlapped with those of metabolic disorder therapeutics. CYP3A4, ABCB1 and ALB are the most shared pharmacogenes. Fifteen COVID-19 therapeutics were predicted as likely drug-drug interaction candidates when used with four CYP inhibitor drugs.Conclusion:
Our findings provide actionable insights for future validation studies and improved clinical decisions for COVID-19 therapy in Indians.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Topics:
Variants
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Pharmacogenomics
Journal subject:
Pharmacology
/
Genetics, Medical
Year:
2021
Document Type:
Article
Affiliation country:
Pgs-2021-0028
Similar
MEDLINE
...
LILACS
LIS